Fulcrum Therapeutics Inc

+0.36 (+3.18%)
Other Pre-Announcement

Fulcrum Therapeutics Reports Q3 Loss Per Share $0.70

Published: 11/10/2020 12:57 GMT
Fulcrum Therapeutics, Inc. (FULC) - Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results.
Qtrly Net Loss per Share $0.70.
Redux4 Trial Progressing; Full Data With Losmapimod in Facioscapulohumeral Muscular Dystrophy (fshd) Expected in 2q 2021.
On Track to Begin Dosing Healthy Volunteers in a Phase 1 Trial for Sickle Cell Disease With Ftx-6058 Before Year-end 2020.
Q3 Earnings per Share View $-0.65 -- Refinitiv Ibes Data (analyst estimates).